Skip to content

Sun Pharma profit may decline 10% in Q3 on poor operating performance

Company likely to report a muted operating performance in Q3FY23, with an EBITDA margin growth estimated flat at 26.2 percent on a year-on-year (YoY) basis. Analysts attribute the steady sale of its specialty products in the US to aid EBITDA margin growth.

Read More

​ Company likely to report a muted operating performance in Q3FY23, with an EBITDA margin growth estimated flat at 26.2 percent on a year-on-year (YoY) basis. Analysts attribute the steady sale of its specialty products in the US to aid EBITDA margin growth. Company likely to report a muted operating performance in Q3FY23, with an EBITDA margin growth estimated flat at 26.2 percent on a year-on-year (YoY) basis. Analysts attribute the steady sale of its specialty products in the US to aid EBITDA margin growth.  Moneycontrol Latest News Read More  

Leave a Reply

Your email address will not be published. Required fields are marked *

en_USEnglish